

REMARKS

By the amendment submitted herewith, claims 205 and 206 have been added. Thus, claims 202-206 are pending.

In accordance with 37 C.F.R. § 1.607, Applicants respectfully request that an interference be declared between the above-identified application and U.S. Patent Nos. 6,207,646 and 6,194,388. The information required by 37 C.F.R. § 1.607(a) is set forth below under headings which correspond to the subsection of § 1.607(a) to facilitate consideration by the Examiner. Applicants have also included completed PTO Forms 850 for the requested interference to facilitate discussion with an Interference Specialist and an Administrative Patent Judge at the appropriate time. The completed Forms are attached as Appendix K.

For the Examiner's convenience, this submission is intended to substitute for the request for interference filed October 31, 2001.

I. Examiner Interviews

Applicants thank Examiners Q. Nguyen and D. Nguyen for extending the courtesy of an interview with Applicants' representatives and the licensee's representatives on October 2, 2001, March 4, 2002 and April 25, 2002, during which this request for an interference was discussed. Applicants appreciate the Examiners' attention and suggestions, which are addressed herein.

II. Compliance with 37 C.F.R. § 1.607(a)(1): Identification of the patents which claim subject matter which interferes with a claim in the application

Applicants request that an interference be declared between Applicants' application ("the application") and U.S. Patent No. 6,207,646, which issued March 27, 2001, to Arthur M. Krieg et al. (the "Krieg '646 patent") and U.S. Patent No. 6,194,388, which issued February 27, 2001, to Arthur M. Krieg et al. (the "Krieg '388 patent").

The Krieg '646 patent issued from U.S. Serial No. 08/738,652, filed October 30, 1996, and states on its face that the '652 application is a "[c]ontinuation of application No. 08/386,063,

filed on Feb. 7, 1995, which is a continuation-in-part of application No. 08/276,358, filed on Jul. 15, 1994, now abandoned.”¹ The Krieg ‘388 patent issued from U.S. Serial No. 08/386,063, filed February 7, 1995, and states on its face that the ‘063 application is a “[c]ontinuation-in-part of application No. 08/276,358, filed on Jul. 15, 1994, now abandoned.” For the Examiner’s convenience, copies of the Krieg ‘646 patent and the Krieg ‘388 patent are attached.

A. Claims 202, 203 and 206 and corresponding claim 7 in the Krieg ‘646 patent are directed to the same invention

The following chart provides a side-by-side comparison of claim 7 of the Krieg ‘646 patent (written in independent form) and claim 202.

Krieg Claim 7 (U.S. 6,207,646)	Carson Claim 202
A composition comprising: a plasmid including an immunostimulatory nucleic acid sequence,	A composition comprising: a plasmid including an immunostimulatory nucleic acid sequence
comprising: 5’X ₁ X ₂ CGX ₃ X ₄ 3’ wherein C is unmethylated, wherein X ₁ , X ₂ , X ₃ , and X ₄ are nucleotides and an antigen in a pharmaceutically acceptable carrier, wherein X ₁ X ₂ are nucleotides selected from the group consisting of: GpT, GpG, GpA and ApA; and X ₃ X ₄ are nucleotides selected from the group consisting of: TpT, CpT, GpT, and TpG.	comprising: AACGTT wherein C is unmethylated, and an antigen in a pharmaceutically acceptable carrier, wherein the antigen is encoded in the plasmid.

Claim 202 is a substantial copy of claim 7 (plasmid containing immunostimulatory CG-containing sequence AACGTT) in conjunction with claim 10 (wherein the antigen is encoded in

¹ As discussed in Section IX, the statement on the face of the Krieg ‘646 patent that the ‘652 application is a continuation of the ‘063 application (filed February 7, 1995), is incorrect. There is new matter in the ‘652 application, and thus it should have been referred to as a continuation-in-part of the ‘063 application.

a DNA vaccine) of the Krieg '646 patent. Thus, both claim 202 and claim 7 recite a CG-containing sequence. Claim 202 imports a substantial copy of the limitation of claim 10 of the Krieg '646 patent, namely, that the antigen is encoded in a DNA vaccine. Claim 202 recites that the antigen is encoded in the plasmid. As is well known in the art, a DNA vaccine is a polynucleotide vector, typically a DNA plasmid, comprising a sequence that encodes an antigen of interest, which antigen is in turn expressed in the host to generate an immune response. Thus, had claim 10 of the Krieg '646 patent depended upon claim 7 instead of claim 6, Applicants' claim 202 would have been almost an exact copy of that claim.

One question raised during the interviews was whether the term "antigen" in claim 7 of the Krieg '646 patent encompasses an antigen encoded by a nucleic acid. As discussed above, dependent claim 10 of the Krieg '646 patent recites that the "antigen is encoded in a DNA vaccine." Furthermore, the specification of the Krieg '646 patent states that "[w]hen the vaccine is a DNA vaccine at least two components determine its efficacy. First, the antigen encoded by the vaccine determines the specificity of the immune response. Second, if the backbone of the plasmid contains CpG motifs, it functions as an adjuvant for the vaccine." Col. 33, lines 38-42. Moreover, Applicants respectfully remind the Office that the test for determining whether claims are directed to the same invention is whether one claim is anticipated or rendered obvious in view of the other claim. 37 C.F.R. § 1.601(n). In this context, an "antigen" and an antigen encoded by a nucleic acid sequence are obvious variants, which is discussed further below.

Claim 203 recites a species of claim 202, namely, pREP7 encoding an antigen. There is no corresponding claim in the Krieg '646 patent.

New claim 206 recites a pharmaceutical composition comprising a species of claim 202, namely, pREP7 encoding an antigen, and a pharmaceutically acceptable carrier. There is no corresponding claim in the Krieg '646 patent.

B. Claim 204 and corresponding claim 3 in the Krieg '646 patent are directed to the same invention

Pending claim 204 is a substantial copy of claim 3 of the Krieg '646 patent.

The following chart provides a side-by-side comparison of claim 3 of the Krieg '646 patent and claim 204.

Krieg Claim 3 (U.S. 6,207,646)	Carson Claim 204 ('191)
A method for desensitizing a subject against the occurrence of an allergic reaction in response to contact with a particular allergen,	A method of treating an allergy in a vertebrate,
comprising administering to the subject an effective amount of an immunostimulatory nucleic acid,	comprising administering to the vertebrate an effective amount of an immunostimulatory nucleic acid in a plasmid,
comprising: 5'X ₁ CGX ₂ 3' wherein the immunostimulatory nucleic acid includes at least 8 nucleotides and wherein C is unmethylated and wherein X ₁ and X ₂ are nucleotides	said immunostimulatory nucleic acid comprising 5'CG3', wherein C is unmethylated,
and an effective amount of the allergen.	and an effective amount of an antigen which stimulates production of allergy-associated IgE antibodies in the vertebrate, wherein said antigen is encoded in the plasmid.

Appendix A provides a discussion of why these claims are directed to the same invention.

In summary:

- Both claim preambles are directed to a method of treating an allergy, which, as is well-known in the art, involves an effort to desensitize a subject or vertebrate such that the extent of an allergic reaction is reduced upon exposure to the offending antigen (allergen).
- The Krieg '646 patent specification refers to "desensitization therapy for allergies." Col. 34, lines 6-9; *see also* col. 6, lines 62-65, and col. 34, lines 18-26.
- Both preamble recitations aim for the same goal that is well recognized in the art: reduction of allergy-associated IgE antibodies, which mediate the unpleasant

symptoms of allergy (such as histamine release, leading to runny eyes, itching, etc.). While Applicants' recitation is more concise than that of claim 3 of Krieg '646, both convey the same concept and objective via reduction of allergy-associated IgE production.

- Claim 3 of the Krieg '646 patent recites that the recipient of the treatment is a "subject", which is defined in the specification as "a human or vertebrate animal..." Col. 13, lines 27-29. Applicants' claim 204 recites "vertebrate".
- A plasmid is an obvious polynucleotide species in view of a polynucleotide of at least 8 nucleotides in length, and vice versa. In a plasmid, the recitation of X₁, X₂, etc. is rendered superfluous, as the CG sequence would *de facto* always be flanked by other nucleotides. The recitation of at least 8 nucleotides is also rendered superfluous, as a plasmid must have at least 8 nucleotides. Conversely, a plasmid anticipates a polynucleotide of at least 8 nucleotides in length.
- Claim 3 of the Krieg '646 patent recites "allergen". One skilled in the art would readily recognize that an allergen is an antigen that stimulates an allergic response, and that an allergy in turn is an inappropriate immune response to the offending antigen.
- It is also well known in the art that a hallmark of an allergic response is production of allergy-associated IgE antibodies in the subject having the allergic reaction. The Krieg '646 patent specification states that allergies "are generally caused by IgE antibody generation". Col. 34, lines 7-9. Thus "allergen" and "an antigen which stimulates production of allergy-associated IgE antibodies" are essentially the same recitations.
- Claim 3 of the Krieg '646 patent recites that an "allergen" is administered. Applicants' claim recites an obvious variation of administering the offending antigen, namely, that the antigen is encoded in the plasmid. Conversely, administering an antigen *per se* is obvious in view of administering an antigen which is encoded in a

plasmid (polynucleotide). One of ordinary skill would recognize that the delivery of an antigen encoded by a plasmid is an obvious alternative with respect to delivery of antigen *per se*. In terms of result, both an “antigen” and an “antigen encoded in a plasmid” stimulate an antigen-specific immune response. Applicants also point out that claims of the Krieg ‘646 patent use these terms interchangeably (see, for example, claim 4).

- During previous prosecution of this application, a restriction requirement issued based on administration of antigen as a polypeptide and administration of antigen in the form of polynucleotide encoding the antigen and was withdrawn by the Office in favor of an election of species requirement. During an interview on November 28, 2000 with Applicants’ representatives, the Examiners acknowledged that claims directed to the administration of antigen as a polypeptide and claims directed to administration of a polynucleotide encoding the antigen were species of a generic claim directed to administration of an antigen and were not subject to a restriction requirement. In the Interview Summary, the Office referred to antigen *per se* and antigen encoded by polynucleotide as forms of antigen administered. Paper No. 19.

Moreover, as stated in the Declaration of inventor Dennis Carson, M.D., submitted herewith, “[i]n the context of allergy immunotherapy, i.e., when offending antigen is administered for the purpose of suppressing the extent of the unwanted immune response (also referred to as desensitization), the desired effect is for the body to respond to the offending antigen in an antigen-specific manner, leading to suppression of the allergic response to that particular antigen. In this context, administration of an antigen or administration of a polynucleotide encoding the antigen, for example a plasmid, serves the same purpose, i.e., the introduction of the antigen to the body.” Dr. Carson also states that, as of the January 30, 1996 filing date of this application, one skilled in the art would have recognized that administering an antigen could be substituted by administering a polynucleotide encoding the antigen, and that, in

terms of the goal of effecting suppression of the allergic response (or desensitization) in allergy immunotherapy, either antigen per se or antigen encoded in polynucleotide can be used.

C. Claim 205 and corresponding claim 3 in the Krieg '646 patent are directed to the same invention

New claim 205 is a substantial copy of claim 3 of the Krieg '646 patent.

The following chart provides a side-by-side comparison of claim 3 of the Krieg '646 patent and new claim 205.

Krieg Claim 3 (U.S. 6,207,646)	Carson Claim 205 ('191)
A method for desensitizing a subject against the occurrence of an allergic reaction in response to contact with a particular allergen,	A method for suppressing an allergic response to an antigen in a mammal susceptible to an allergic reaction to said antigen which stimulates production of allergy-associated IgE antibodies in the mammal,
comprising administering to the subject	comprising parenterally administering to the mammal
an effective amount of an immunostimulatory nucleic acid,	(a) an effective amount of an immunostimulatory nucleic acid in a plasmid,
comprising: 5'X ₁ CGX ₂ 3' wherein the immunostimulatory nucleic acid includes at least 8 nucleotides and wherein C is unmethylated and wherein X ₁ and X ₂ are nucleotides	said immunostimulatory nucleic acid comprising 5'CG3', wherein C is unmethylated,
and an effective amount of the allergen.	and (b) an effective amount of the antigen or the antigen encoded in the plasmid.

Appendix A provides a discussion of why these claims are directed to the same invention.

In summary:

- Both claim preambles are directed to a method for suppressing an allergic response to an antigen, which, as is well-known in the art in the context of allergy immunotherapy, involves an effort to desensitize a subject or mammal such that the extent of an allergic reaction is reduced or suppressed upon exposure to the offending antigen (allergen).

- The Krieg '646 patent specification refers to “desensitization therapy for allergies.” Col. 34, lines 6-9; *see also* col. 6, lines 62-65, and col. 34, lines 18-26.
- Both preamble recitations aim for the same goal that is well recognized in the art: reduction of allergy-associated IgE antibodies, which mediate the unpleasant symptoms of allergy (such as histamine release, leading to runny eyes, itching, etc.). Both Applicants' recitation and that of claim 3 of Krieg '646 convey the same concept and objective via reduction of allergy-associated IgE production.
- Claim 3 of the Krieg '646 patent recites “allergen”. One skilled in the art would readily recognize that an allergen is an antigen that stimulates an allergic response, and that an allergy in turn is an inappropriate immune response to the offending antigen.
- It is also well known in the art that a hallmark of an allergic response is production of allergy-associated IgE antibodies in the subject having the allergic reaction. The Krieg '646 patent specification states that allergies “are generally caused by IgE antibody generation”. Col. 34, lines 7-9. Thus “allergen” and “the antigen which stimulates production of allergy-associated IgE antibodies” are essentially the same recitations.
- Claim 3 of the Krieg '646 patent recites that the recipient of the treatment is a “subject”, which is defined in the specification as “a human or vertebrate animal...” Col. 13, lines 27-29. Of the specific subjects listed in this recitation, 11 of the 12 are mammals. Applicants' claim 205 recites “mammal”. Thus, in this context, “mammal” is an obvious variant of “subject.”
- The recitation of “administering” in claim 3 of the Krieg '646 patent clearly includes the “parenterally administering” recited in claim 205. The Krieg '646 patent lists parenteral administration among the routes of administration appropriate for the immunostimulatory nucleic acids.

- A plasmid is an obvious polynucleotide species in view of a polynucleotide of at least 8 nucleotides in length, and vice versa. In a plasmid, the recitation of X₁, X₂, etc. is rendered superfluous, as the CG sequence would *de facto* always be flanked by other nucleotides. The recitation of at least 8 nucleotides is also rendered superfluous, as a plasmid must have at least 8 nucleotides. Conversely, a plasmid anticipates a polynucleotide of at least 8 nucleotides in length.
- Claim 3 of the Krieg '646 patent recites that an "allergen" is administered. Applicants' claim 205 is written in the alternative and recites administration of the offending antigen or an obvious variation of administering the offending antigen, namely, that the antigen is encoded in the plasmid. Conversely, administering an antigen *per se* is obvious in view of administering an antigen which is encoded in a plasmid (polynucleotide). One of ordinary skill would recognize that the delivery of an antigen encoded by a plasmid is an obvious alternative with respect to delivery of antigen *per se*. In terms of result, both an "antigen" and an "antigen encoded in a plasmid" stimulate an antigen-specific immune response. Applicants also point out that claims of the Krieg '646 patent use these terms interchangeably (see, for example, claim 4).
- During previous prosecution of this application, a restriction requirement issued based on administration of antigen as a polypeptide and administration of antigen in the form of polynucleotide encoding the antigen and was withdrawn by the Office in favor of an election of species requirement. During an interview on November 28, 2000 with Applicants' representatives, the Examiners acknowledged that claims directed to the administration of antigen as a polypeptide and claims directed to administration of a polynucleotide encoding the antigen were species of a generic claim directed to administration of an antigen and were not subject to a restriction requirement. In the Interview Summary, the Office referred to antigen *per se* and antigen encoded by polynucleotide as forms of antigen administered. Paper No. 19.

Moreover, as stated in the Declaration of inventor Dennis Carson, M.D., submitted herewith, “[i]n the context of allergy immunotherapy, i.e., when offending antigen is administered for the purpose of suppressing the extent of the unwanted immune response (also referred to as desensitization), the desired effect is for the body to respond to the offending antigen in an antigen-specific manner, leading to suppression of the allergic response to that particular antigen. In this context, administration of an antigen or administration of a polynucleotide encoding the antigen, for example a plasmid, serves the same purpose, *i.e.*, the introduction of the antigen to the body.” Dr. Carson also states that, as of the January 30, 1996 filing date of this application, one skilled in the art would have recognized that administering an antigen could be substituted by administering a polynucleotide encoding the antigen, and that, in terms of the goal of effecting suppression of the allergic response (or desensitization) in allergy immunotherapy, either antigen *per se* or antigen encoded in polynucleotide can be used.

Applicants wish to point out that to provoke an interference, claims of the Krieg ‘646 patent were substantially copied. Thus, most claim limitations are those that were examined and approved by the Examiner who allowed the Krieg ‘646 patent. Applicants’ claims and the Krieg claims discussed above are directed to the same invention.

III. Compliance with 37 C.F.R. § 1.607(a)(2): Presenting a proposed count

Applicants present proposed counts 1 and 2 in Appendix B, each of which is formulated in the alternative.

A. Discussion of Proposed Count 1

The first alternative is identical to Applicants’ claim 202. The second alternative is identical to claim 7 of the Krieg ‘646 patent, and differs insubstantially from the first alternative, as discussed below.

Both alternatives recite “a plasmid including an immunostimulatory nucleic acid sequence”. Both alternatives recite that the immunostimulatory sequence contains a “CG” dinucleotide sequence and that the C is unmethylated.

The first alternative recites nucleotide sequences flanking the “CG” dinucleotide sequence as “AA” and “TT”, which is identical to a species recited in claim 7 of the Krieg ‘646 patent and in the second alternative. The second alternative recites that flanking sequences X_1X_2 are selected from the group consisting of GpT, GpG, GpA, and ApA; and that flanking sequences X_3X_4 are selected from the group consisting of TpT, CpT, GpT, and TpG. Applicants also point out that, in the context of a plasmid, which is circular DNA, there must always be flanking nucleotides with respect to a “CG” found in that plasmid.

The first alternative recites that the antigen “is encoded in the plasmid”. The second alternative recites an “antigen”. In this context, the phrases are equivalent and not patentably distinct (*i.e.*, are obvious variants). The Examiner is referred to the above discussion and Appendix A comparing Applicants’ claims 204 and 205 particularly the subsection “wherein said antigen is encoded in the plasmid” and Krieg claim 3, which is applicable to comparing the proposed counts and reaching the conclusion that the proposed counts are substantially the same and are directed to the same invention.

B. Discussion of Proposed Count 2

The first alternative is identical to Applicants’ claim 205. The second alternative is identical to claim 3 of the Krieg ‘646 patent and differs insubstantially from the first alternative. As discussed above and in Appendix A, claim 205 and claim 3 of the Krieg ‘646 patent are directed to the same invention. Therefore, it is proper to include them as two alternatives of the same count.

IV. Compliance with 37 C.F.R. § 1.607(a)(3): Identification of claims of the Krieg '646 and '388 patents which correspond to the proposed counts

A. Proposed Count 1

1. Krieg '646 patent claims 1-2, 4, 6-11, 13-37, and 39 correspond to proposed count 1

Applicants identify claims 1-2, 4, 6-11, 13-37, and 39 of the Krieg '646 patent as corresponding to proposed count 1. Appendix C provides a claim-by-claim explanation as to why these Krieg '646 patent claims correspond to proposed count 1. For the Examiner's convenience, the composition claims are presented first, followed by the method claims. Applicants submit that the method claims are obvious in view of proposed count 1 directed to the immunostimulatory compositions and thus correspond to the count.

2. Krieg '388 patent claims 1-2, 4, 6-9, 13-19, and 21-22 correspond to proposed count 1

Applicants identify claims 1-2, 4, 6-9, 13-19, and 21-22 of the Krieg '388 patent as corresponding to proposed count 1. Appendix D provides a claim-by-claim explanation as to why these Krieg '388 patent claims correspond to proposed count 1. For the Examiner's convenience, the composition claims are presented first, followed by the method claims. Applicants submit that the method claims are obvious in view of proposed count 1 directed to the immunostimulatory compositions and thus correspond to the count.

B. Krieg '646 patent claims 3, 11, 12, 17, 21, 25, 27, 37, and 38 correspond to proposed count 2

Applicants identify Krieg '646 patent claims 3, 11, 12, 17, 21, 25, 27, 37 and 38 as corresponding to proposed count 2. All of the dependent claims (11, 12, 17, 21, 25, 27, 37 and 38) are directed to compositions containing an allergen. Appendix E provides a claim-by-claim explanation as to why these Krieg '646 patent claims correspond to proposed count 2. As a preliminary matter, claims 11, 17, 21, 25 and 37 recite Markush groups which recite, inter alia, "allergen" as a species of antigen, and to the extent "allergen" is contained in the Markush group these claims correspond to the count, as discussed more fully in Appendix E. Applicants submit

that the above claims do not define separate patentable inventions within the meaning of 37 C.F.R. § 1.601(n).

V. Compliance with 37 C.F.R. § 1.607(a)(4): Presenting claims from the application which correspond to the proposed counts

Applicants identify claim 202 as corresponding exactly to the first alternative of proposed count 1, and claim 203 and new claim 206 that correspond substantially thereto.

Applicants identify new claim 205 as corresponding exactly to the first alternative of proposed count 2, and claim 204 that corresponds substantially thereto.

VI. Compliance with 37 C.F.R. § 1.607(a)(5): Applying the terms of the application claims corresponding to the proposed count to the disclosure of the application

A. Claims 202, 203 and 206

In Appendix F, Applicants list exemplary support for the limitations of claims 202, 203 and new claim 206 in the instant application ('191). However, the listing in Appendix F is only exemplary and Applicants expressly reserve the right to refer to additional passages if deemed necessary.

B. Claims 204 and 205

In attached Appendix G, Applicants list exemplary support in the instant application ('191) for the limitations of claim 204 and new claim 205. However, the listing in Appendix G is only exemplary and Applicants expressly reserve the right to refer to additional passages if deemed necessary.

VII. Compliance with 37 C.F.R. § 1.607(a)(6): Requirements of 35 U.S.C. § 135(b) are met

Claims 202-204, submitted October 31, 2001 in an Amendment and Request for Interference under 37 C.F.R. § 1.607, were presented within one year of issuance of the Krieg

'646 patent (which issued March 27, 2001) and the Krieg '388 patent (which issued February 27, 2001). Pre-issuance publication of the patent applications corresponding to the Krieg '646 and '388 patents did not occur, as these applications were filed before November 29, 2000.

VIII. Compliance with 37 C.F.R. § 1.608

Applicants have an earlier effective filing date, and thus should be designated as senior party with respect to both counts. As such, no showing pursuant to § 1.608 is required. Applicants are entitled to priority benefit of the filing date of U.S. Serial No. 08/112,440, filed August 26, 1993, and U.S. Serial No. 08/446,691, filed June 7, 1995, because both prior applications disclose at least a constructive reduction to practice of the species of claims 203 and 206, which species fall within the genus of claim 202, and thus proposed count 1.

An exemplary showing of the passages in the grandparent and great-grandparent applications which constitute a constructive reduction to practice of proposed count 1 is set forth in Appendix H. The great-grandparent application U.S. Serial No. 08/112,440 describes AACGTT-containing antigen-encoding plasmids that may be used to generate an immune response. An antigen-encoding plasmid based on the vector pREP7, which is a species of claim 202, is described in the instant application on page 26, lines 5-6, the grandparent application U.S. Serial No. 08/446,691, on page 33, lines 1-2, and the great-grandparent application U. S. Serial No. 08/112,440, on page 23, lines 17-18 (and in Example I). The great-grandparent specification also states that this plasmid was publicly available from Invitrogen (San Diego, CA) at page 23, lines 17-18. A map of pREP7 from Invitrogen is provided in Appendix I. This plasmid contains an ampicillin resistance gene, which in turn contains the immunostimulatory CG-containing sequence AACGTT. Construction of an antigen-expressing vector pREVk3 based on pREP7 is disclosed in Example I (pages 32-33). The antigen-encoding insert in the pREP7 is Humkv325, a rearranged kappa light gene from a human patient with chronic lymphocytic leukemia. Thus, the great-grandparent application (U.S. Serial No. 08/112,440), having a filing date of August

26, 1993, discloses an antigen encoding plasmid having the immunostimulatory sequence AACGTT, which appears in the first alternative of proposed count 1.²

The Krieg '646 patent issued from U.S. Serial No. 08/738,652, filed October 30, 1996, which claims priority benefit from U.S. Serial No. 08/386,063 (filed February 7, 1995), and U.S. Serial No. 08/276,358 (filed July 15, 1994). The Krieg '388 patent issued from U.S. Serial No. 08/386,063 (filed February 7, 1995), which is the immediate parent of the specification which gave rise to the Krieg '646 patent, and which claims priority benefit of U.S. Serial No. 08/276,358 (filed July 15, 1994).

Applicants are entitled to a filing date of August 26, 1993, which is eleven (11) months before the earliest U.S. filing date (July 14, 1994) of the application which matured into the Krieg '646 patent and the Krieg '388 patent. There is thus no requirement for Applicants to submit a statement that there is a basis upon which Applicants are entitled to a judgment relative to the Patentee. Nor is any showing pursuant to 37 C.F.R. § 1.608(b) required.

IX. Establishing Applicant as Senior Party in accordance with 37 C.F.R. § 1.601(m)

With respect to proposed count 1, neither of the two parent cases of the Krieg '646 patent contains any disclosure pertaining to plasmids (as recited in the proposed count 1). The same is true with respect to the Krieg '388 patent. Thus the earliest date to which Krieg is entitled for proposed count 1 is October 30, 1996, whereas Applicants are entitled to a filing date of August 26, 1993, for proposed count 1.

With respect to proposed count 2, although the Krieg '646 patent claims priority benefit from U.S. Serial No. 08/386,063 (filed February 7, 1995), and U.S. Serial No. 08/276,358 (filed July 15, 1994), neither of the two parent cases contains any disclosure pertaining to claim 3 or the allergen-containing compositions (and methods) of claims 11, 12, 17, 21, 25, 27, 37 and 38

² As described in the instant specification, the sequence AACGTT is immunostimulatory. See, e.g., page 11, line 15 to page 13, line 2, and cited Examples.

of the Krieg '646 patent or of proposed count 2. Thus, the effective filing date of this claimed subject matter is October 30, 1996, whereas Applicants are entitled to the earlier January 30, 1996, filing date of the U.S. Serial No. 08/593,554, for proposed count 2.

Related Krieg patent applications

Applicants wish to bring to the Examiner's attention U.S. Serial Nos. 09/337,893, and 09/337,584. According to the prosecution history of the Krieg '646 patent (*see* amendment dated September 15, 1999; paper no. 19, in conjunction with amendment dated December 22, 1998; paper no. 12, which presents claims referred to in paper no. 19, copies attached as Appendix J), each of these applications contains at least one claim that is related to proposed count 2. The Examiner is respectfully requested to review the related Krieg applications to determine whether claims in those applications should be involved in the requested interference.

CONCLUSION

Applicants are presumptively the prior inventors of the claimed subject matter and desire that an interference be declared using the proposed counts 1 and 2 set forth in Appendix B. Applicants further submit that the following claims correspond to the proposed counts: claims 1-2, 4, 6-11, 13-37, and 39 of the Krieg '646 patent, claims 1-2, 4, 6-9, 13-19, and 21-22 of the Krieg '388 patent, and claims 202, 203 and 206 of the instant application, correspond to proposed count 1; and claims 3, 11, 12, 17, 21, 25, 27, 37, and 38 of the Krieg '646 patent, and claims 204 and 205 of the instant application correspond to proposed count 2. The Applicants' opportunity to prove that they are the actual prior inventors should not be unduly delayed.


In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this

document to **Deposit Account No. 02-4800**, referencing docket no. 028723-306. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: May 9, 2002

By:


R. Danny Huntington
Registration No. 27,903

BURNS, DOANE, SWECKER & MATHIS LLP
P.O. Box 1404
Alexandria, Virginia 22313-1404
Telephone: (703) 836-6620
Facsimile: (703) 836-2021